Ennogen

What Ennogen does

Ennogen Healthcare International Limited is a UK-registered specialty pharmaceutical and medical device company headquartered in Dartford, UK, with international operations spanning Ireland and Dubai and direct sales coverage across more than 11 European countries plus the Middle East. Founded in 2011 by John Ruprai, the company pursues a brand-acquisition strategy: it identifies heritage pharmaceutical brands that have become underserved or discontinued by larger manufacturers, acquires the marketing authorizations and trademarks (most recently the Axsain and Zacin capsaicin cream portfolio from Teva UK in June 2025), and re-commercializes them across dermatology, respiratory, otology, blood pressure, and pain relief therapeutic areas. The product portfolio serves patients with chronic conditions through healthcare providers and distributors in B2B channels.

The business model is built on pharmaceutical and medical device product sales to healthcare providers and distributors across Europe, the UK, and the Middle East. Revenue is generated via direct enterprise field sales rather than disclosed licensing economics, though the company does not publicly disclose pricing or unit economics. The operating model emphasizes supply chain security, ISO 13485-certified quality management, efficient technical transfers for new product onboarding, and selective R&D to improve acquired brands. Growth has been achieved both organically and through multiple acquisitions over the past three years with large multinational pharmaceutical companies, funded historically through cash flow and shareholder injections and increasingly through institutional debt: a £30m facility from Santander UK in May 2024, upsized to a £150m syndicated facility (Santander UK, Barclays, HSBC UK) in July 2025.

The company employs more than 70 staff across its UK, Irish, and Middle East locations as of July 2025, up from approximately 50 in May 2024. Management combines long-tenured pharmaceutical operators (including a CFO who previously helped grow and sell Sinclair Pharma for £163m in 2018) with specialized international sales, technical/regulatory, and business development hires. Customers are healthcare providers and B2B distributors rather than named large-anchor accounts, and the company partners with EU regulatory representatives (such as Elara Pharmaservices in Ireland) to support medical device distribution. Risks include concentrated debt reliance, dependence on continued availability of acquisition targets from divesting multinationals, regulatory approval continuity, and execution risk in international expansion across multiple therapeutic areas simultaneously.

Name

Ennogen

Legal name

Ennogen Healthcare International Limited

Website

https://ennogen.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Ennogen Healthcare International Limited is a UK-registered specialty pharmaceutical and medical device company that acquires and reinvigorates heritage pharma brands across dermatology, respiratory, otology, blood pressure, and pain relief, selling to healthcare providers and distributors across Europe, the UK, and the Middle East.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Pharmaceutical products
• Medical devices
• Dermatology treatments
• Pain management
• Respiratory medications

Headquarters

HQ city

Dartford

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and distributing pharmaceutical products across dermatology, respiratory, otology, blood pressure and pain relief therapeutic areas. The company reinvigorates heritage brands to meet underserved clinical need.
2. Medical Device Sales: Revenue from medical device products in addition to pharmaceuticals, with global footprint across Europe and other specific territories.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Ennogen acquires and reinvigorates heritage pharmaceutical and medical device brands to meet underserved clinical needs in five therapeutic areas: dermatology, respiratory, otology, blood pressure, and pain relief. The company manufactures and distributes products such as the Capsaicin 0.075% (Axsain) and 0.025% (Zacin) topical pain relief creams, alongside a broader specialty pharma and medical device portfolio targeted predominantly at chronic-condition patients across Europe, the UK, and the Middle East.

Product overview

Ennogen Healthcare International Ltd is an international pharmaceutical and medical device company that operates across five key therapeutic areas: dermatology, respiratory, otology, blood pressure, and pain relief. The company follows a strategy of acquiring and reinvigorating heritage pharmaceutical brands to meet underserved clinical needs. Its product portfolio includes topical pain relief treatments such as Capsaicin creams (Axsain 0.075% and Zacin 0.025%), as well as medical devices. The company has expanded internationally through multiple acquisitions, building an extensive portfolio of products targeting patients with chronic conditions across Europe, the UK, and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

• Axsain: Capsaicin 0.075% cream for pain relief, acquired from Teva UK.
• Zacin

Products and services

• Capsaicin 0.075% (Axsain) Cream A topical capsaicin 0.075% cream for pain relief indicated for neuropathic pain conditions, acquired from Teva UK and sold to healthcare providers and pharmacies.
• Capsaicin 0.025% (Zacin) Cream A topical capsaicin 0.025% cream for pain relief indicated for mild to moderate pain conditions, acquired from Teva UK and sold to healthcare providers and pharmacies.
• Dermatology Products Portfolio Pharmaceutical products focused on dermatological conditions, including topical treatments for skin disorders and pain management, distributed to healthcare providers across Europe and the Middle East.
• Respiratory Products Portfolio Pharmaceutical products addressing respiratory conditions targeting patients with chronic respiratory diseases, distributed to healthcare providers across Europe and the Middle East.
• Pain Relief Products Portfolio Pharmaceutical products for pain management including topical analgesics (e.g., Axsain 0.075% and Zacin 0.025% Capsaicin creams) and chronic pain treatments, distributed to healthcare providers across Europe and the Middle East.
• Otology Products Pharmaceutical products focused on ear-related conditions, one of five key therapeutic areas for the company.
• Blood Pressure Products Pharmaceutical products addressing blood pressure management, one of five key therapeutic areas for the company.
• Medical Devices Medical device products distributed across international markets including the UK and Ireland, manufactured and supplied under the company's ISO 13485-accredited quality management system.

Quantifiable outcome

• Multiple transactions completed with large multinational industry leaders over three years
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• Elara Pharmaservices Europe LtdminorChannel Partner/ Reseller/ DistributorEU Representative for Ennogen Healthcare medical devices in Ireland. Located at Regus Block 1, Office 107, D15 AKK1, Dublin 15, Ireland.
• Hill Dickinson LLPminorImplementation/ SI/ Consulting PartnerLegal counsel supporting the £150m syndicated financing facility transaction.
• Addleshaw GoddardminorImplementation/ SI/ Consulting PartnerLegal guidance provided by Sarah Jay and James Garner at Addleshaw Goddard for the financing transaction.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Consilient Health: UK-headquartered specialty pharma focused on women's health, dermatology, and pain management. Comparable niche-heritage-brand strategy and therapeutic area overlap (dermatology, pain relief) with similar UK/EU distribution model.
• Sinclair Pharma: Specialty aesthetics and dermatology pharma company; Ennogen CFO Jason Tate previously helped grow Sinclair Pharma before its £163m sale to Huadong Medicine in 2018. Directly comparable heritage-brand specialty pharma operating model.
• Alliance Pharma: UK-listed specialty pharma that acquires and markets established healthcare brands across multiple therapeutic areas. Directly comparable niche-brand roll-up model with similar focus on dermatology, pain, and respiratory categories.

Broad incumbents

• Almirall: Spain-based global dermatology-focused pharmaceutical company. Overlaps with Ennogen's dermatology franchise but operates at significantly larger scale with proprietary R&D pipeline.
• Dermapharm Holding: German specialty pharma with leading dermatology franchise and parallel branded/generic model. Comparable in therapeutic focus (dermatology) and brand-acquisition approach, but at much larger scale with public-market capital.
• Stada Arzneimittel: European generics and specialty pharma with significant consumer health/OTC presence including dermatology. Comparable heritage-brand and OTC/dermatology portfolio strategy, though at much larger scale with PE ownership (Cinven/Bain).
• Recordati: European specialty pharma with strong dermatology and rare-disease franchises, known for acquiring heritage brands from larger pharma. Comparable international specialty pharma with dermatology/pain therapeutic overlap.

Emerging players

• AFT Pharmaceuticals: Trans-Tasman specialty pharma focused on pain, dermatology, and OTC categories with international expansion. Comparable therapeutic mix (pain relief, dermatology) and similar heritage-brand/in-licensing growth strategy.
• HRA Pharma: European specialty pharma (acquired by Perrigo) with focus on dermatology, pain, and consumer health OTC. Directly comparable niche specialty pharma roll-up that was itself sold as a strategic asset.

Others

• Teva Pharmaceutical Industries: Global pharma that divested Axsain/Zacin capsaicin brands to Ennogen in 2025 as part of its "Pivot to Growth" program. Functions as a counterparty/divestor and a comparable generic+specialty pharma operator at massive scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ennogen-healthcare-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ennogen